UP Oncolytics raises $2.5M NIH grant to advance Zika-based brain cancer therapy
What's the deal? UP OncolyticsDealroom has a profile for this one. Try Dealroom → has secured $2.5 million in National Institutes of Health (NIH)Dealroom has a profile for this one. Try Dealroom → Phase II SBIR Fast-Track funding to move an engineered Zika virus therapy toward its first human trial. The Milwaukee biotech, a 2022 spinout tied to Rosalind Franklin University's Helix 51 incubator, is developing the treatment for glioblastoma, an aggressive brain tumor. The grant builds on an earlier $500,000 Phase I award.
What's the endgame? The appeal of Zika is biological: the virus naturally crosses the blood-brain barrier, which blocks most chemotherapy from reaching brain tumors. UP Oncolytics is adapting it to target and destroy glioblastoma cells while sparing healthy tissue.
Why now? Glioblastoma kills most patients within roughly 15 months of diagnosis, and treatment has barely changed in two decades. The standard regimen set in 2005 produced a median survival of 14.6 months in newly diagnosed patients, and fewer than 5% survive five years.
What's the money for? The two-year tranche will fund the preclinical package needed to file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA), the formal gateway to enrolling patients. The FDA has already granted Orphan Drug Designation to one of the company's virus strains for malignant gliomas, a step that confers development incentives but says nothing about efficacy.
What could go wrong? The therapy is still preclinical. Filing the IND would trigger FDA review of whether safety data on a re-engineered Zika strain justifies exposing patients to it — a question that will determine whether the approach leaves the lab at all.
The signal: The round sits in the 35th percentile by amount, modest for the sector. But it arrives amid renewed interest in oncolytic-virus approaches for glioblastoma, with rival programs already in clinical testing. UP Oncolytics is betting that Zika's ability to reach the brain gives it an edge conventional drugs cannot match.
Read more: clinicaltrialvanguard.com
Image credit: UP Oncolytics
